DGX vs MTD: Quest Diagnostics and Mettler-Toledo International compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Mettler-Toledo International is the larger company, worth $33.4B, about 1.3 times Quest Diagnostics.
- Quest Diagnostics grew revenue faster over the last year (+10.2% vs +4.5%).
- On earnings, Quest Diagnostics is the cheaper stock (25.0x vs 38.9x).
- Mettler-Toledo International's price assumes faster free cash flow growth: about 14% a year, against 4% for Quest Diagnostics (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | DGX | MTD |
|---|---|---|
| Market cap | $25.0B | $33.4B |
| Share price | $230.97 | $1,549.99 |
| Revenue (last fiscal year) | $11.0B | $4.0B |
| Free cash flow (last fiscal year) | $1.4B | $849M |
| Revenue growth, last year | +10.2% | +4.5% |
| Revenue growth per year, last 5 fiscal years | +0.6% | +2.0% |
| Operating margin | 14.1% | — |
| Net margin | 9.2% | 21.9% |
| Return on equity | 14.1% | 7062.4% |
| P/E (trailing) | 25.0x | 38.9x |
| Price / free cash flow | 18.4x | 39.4x |
| EV / EBITDA | 15.7x | 28.4x |
| FCF growth the price implies | 3.9% | 13.9% |
| Dividend yield | 1.4% | — |
| Debt / equity | 1.21x | 285.3x |
| Fundamental grade | C | C |
| Superinvestors holding it | 5 | 5 |
| Insider purchases, last 12 months | 2 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Quest Diagnostics
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $10.8B | $1.8B | 22.1% |
| 2022 | $9.9B | $1.3B | 14.4% |
| 2023 | $9.3B | $864M | 13.6% |
| 2024 | $9.9B | $909M | 13.6% |
| 2025 | $11.0B | $1.4B | 14.1% |
Mettler-Toledo International
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $3.7B | $801M | — |
| 2022 | $3.9B | $738M | — |
| 2023 | $3.8B | $861M | — |
| 2024 | $3.9B | $864M | — |
| 2025 | $4.0B | $849M | — |
Where the revenue comes from
Quest Diagnostics · by segments, 2025
DIS business$10.8B98%
DS businesses$250M2%
Mettler-Toledo International · by segments, 2025
US Operations$1.5B37%
Western European Operations$896M22%
Other Operations$789M20%
Chinese Operations$635M16%
Swiss Operations$211M5%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open DGX in InvestinglyQuestions
Which is bigger, Quest Diagnostics or Mettler-Toledo International?
Mettler-Toledo International (MTD), at $33.4B against $25.0B.
Is DGX or MTD cheaper?
By trailing P/E, Quest Diagnostics (25.0x) is cheaper than Mettler-Toledo International (38.9x). A lower multiple can also mean the market expects less growth.
Which grows faster, DGX or MTD?
Quest Diagnostics: revenue grew +10.2% over the last year, against +4.5%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.